Long‑term Response of Liver Metastases of Breast Cancer to Capecitabine – Case Report

Česká verzia

Authors: D. Macková
Authors place of work: Klinika komplexní onkologické péče, Masarykův onkologický ústav, Brno
Published in the journal: Klin Onkol 2010; 23(1): 46-48
Category: Kazuistiky

Summary

A case report of a patient with HER2- positive liver metastases of breast cancer. Partial regression was reached during chemotherapy, which was further stabilized by trastuzumab. Resection of the metastases was performed after progression. Capecitabine was started after the occurrence of new multiple lesions; complete regression was reached, which has now lasted over three years with continued capecitabine treatment.

Key words:
breast cancer – liver metastases

Zdroje

1. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2- positive metastatic breast cancer administered as first‑line treatment: the M77001 study group. J Clin Oncol 2005; 23(19): 4265– 4274.

2. Carlini M, Lonardo MT, Carboni F et al. Liver metastases from breast cancer. Results of surgical resection. Hepatogastroenterology 2002; 49(48): 1597– 1601.

3. Lermite E, Marzano E, Chéreau E et al. Surgical resection of liver metastases from breast cancer. Surg Oncol 2009. [Epub ahead of print]

4. Stockler MR, Sourjina T, Grimison P et al. A randomized trial of capecitabine given intermittently rather than continuously compared to classical CMF as first‑line chemotherapy for advanced breast cancer. J Clin Oncol 2007; 25 (Suppl): Abstract 1031.

5. Miles D, Vukelja S, Moiseyenko JA et al. Survival benefit with capecitabine/ docetaxel versus docetaxel alone: Analysis of therapy in a randomized phase III trial. Clinical Breast Cancer 2004; 5(4): 273– 278.

6. Verma S, Wong NS, Trudeau M et al. Survival Differences Observed in Metastatic Breast Cancer Patients Treated With Capecitabine When Compared With Vinorelbine After Pretreatment With Anthracycline and Taxane. Am J Clin Oncol 2007; 30: 297– 302.

7. von Minckwitz G, du Bois A, Schmidt M et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2- positive advanced breast cancer: a german breast group 26/ breast international group 03– 05 study. J Clin Oncol 2009; 27(12): 1999– 2006.

8. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat 2008; 112(3): 533– 543.